Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the…

BMS' Opdivo failed its lung cancer trial a few days ago now, but the pharma world is still digesting the news--and new sales estimates, ripple-effect…

GlaxoSmithKline has struck a money-back guarantee on its gene therapy Strimvelis. The once-and-done treatment for “bubble boy” disease, only the second of its…

Allergan may have a reputation as a serial buyer, but it’s not looking for any big deals, CEO Brent Saunders insisted on Monday.

Note to price-hiking drugmakers: CVS Health is targeting you. The PBM barred 10 new meds from its 2017 formulary for "egregious" price increases, and…

What with long summer days and vacations, it can be tough to keep up with required reading in July. To catch up with the best-read news, check out FiercePharma…

For the third year in a row, Express Scripts unveiled a new national formulary excluding dozens of drugs. And for the third year in a row, a short list of…

Expecting $500 million in cost savings from swallowing Baxalta? Scratch that. New owner Shire now says it can up that figure by 40%.